|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||121.60 - 125.54|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||54.57|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The JPMorgan Healthcare Conference, one of the biggest and most important events of the year for biotech investors, kicks off this week. Last week, Morgan Stanley analyst Matthew Harrison compiled a report ...
Raymond James's Laura Chico takes a look at the biotech landscape for 2018, writing that she's optimistic about the sector, although she's cooled a bit on Alexion Pharmaceuticals (ALXN). Chico writes that regulatory agencies are working "efficiently" to facilitate drug approvals, and the proof was in the pudding, given last year's record number of approvals. Some picks from her note: Heading into 2018, we think the mid-cap space appears attractive, particularly as players like Sage Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE), and Blueprint Medicines Corporation (BPMC) advance late-stage assets closer to the commercial stage.
Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.
Alexion Pharmaceuticals Inc. said Tuesday it will work with hedge fund Elliott Management Corp. on filling an open board seat.
Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board. Elliott, which has built a stake in Alexion, ...
In a note on Tuesday, Geoffrey Porges at Leerink Partners identified Vertex Pharmaceuticals (VRTX) and Alexion Pharmaceuticals (ALXN) as his top two picks among large cap biotechs in 2018, citing their continued dominance in two medical areas. Alexion is slated to move into its new headquarters in Boston’s Seaport District in mid-2018, a couple blocks from where Vertex is located. In his note, Porges said that both Vertex and Alexion are poised to thrive in what he predicts will be a tough environment for Big Pharma, characterized by “hyper-competition, pricing pressure and uncertain M&A activity.” According to Porges, that's because both companies focus on diseases — cystic fibrosis for Vertex, and a rare blood disorder in the case of Alexion — for which there are relatively few serious competitors.
The Dow Jones Industrial Average fell 34.84 points, or 0.1%, to 24,719.22 last week, not big deal. The Nasdaq finished up 28% in 2017, while the Dow gained 25%, and the S&P 500 rose 19%. Including reinvested dividends, the S&P 500 has returned 20% or more 26 times since 1943, and followed that up with another positive year 20 times, says Sadoff Investment Management.
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) will report fourth-quarter earnings in late January, according to Oppenheimer. The Analyst Oppenheimer's Hartaj Singh maintains an Outperform on Alexion ...
No franchise is safe in 2018 among biotechs which are feeling pressure as the FDA speeds approvals for rival medicines.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alexion Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ALXN-US. Comparing the performance and risk of Alexion Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
CNBC's Leslie Picker reports on Alexion collaborating with hedge fund Elliott Management on a new board member for the company.